<DOC>
	<DOCNO>NCT02730923</DOCNO>
	<brief_summary>The investigator hypothesize dual inhibition mTORC1/mTORC2 AZD2014 combine inhibition aromatase enzyme anastrozole act synergistically may interest therapeutic option endometrial cancer manageable toxicity profile . The investigator proposal conduct multicenter , 2-step , randomize , Phase I/II trial evaluate safety efficacy combination treatment associate anastrozole AZD2014 advance endometrial cancer patient . The study divide 2 step : - A safety run-in phase aim evaluate safety propose combination AZD2014 + anastrozole ( Arm A ) versus anastrozole alone ( Arm B ) . No dose escalation schedule ( dos base maximum tolerate dose ( MTD ) define AZD2014 summary product characteristic ( SPC ) anastrozole ) . However , dose de-escalation AZD2014 apply case toxicity . - A two-stage randomized Phase II part aim evaluate clinical benefit AZD2014 + anastrozole ( Arm A ) combination therapy versus anastrozole ( Arm B ) .</brief_summary>
	<brief_title>Hormone Receptor Positive endometrIal Carcinoma Treated Dual mTORC1/mTORC2 Inhibitor Anastrozole ( VICTORIA )</brief_title>
	<detailed_description>TREATMENT PLAN : Following randomisation patient receive Arm A : AZD2014 plus anastrozole Arm B : anastrozole alone AZD2014 administer intermittent schedule i.e . 125 mg bi die ( BID ) intermittent 2 day follow 5 day per week total weekly dose 500 mg/week ( 250mg D1 D2 , 5 day ) Anastrozole administer standard dose define SPC i.e . 1mg/d , per o , continuously . Both treatment administer progressive disease ( PD ) , unacceptable toxicity willingness stop . STATISTICS : A total 72 patient randomize study . Safety run-in Phase first 9 patient randomized - As dose escalation perform , safety evaluate follow treatment 8-week follow-up first 6 patient experimental association AZD2014+anastrozole ( experimental arm ) . By similarity classic 3+3 design , base binomial probability , 90 % probability observe one patient toxicity event , event occurs least 32 % target population . Assuming 2:1 randomization ratio , total 9 patient ( Arm A - Experimental : 6 patient , Arm B - Control : 3 patient ) enrol safety run-in phase include evaluation Phase II part . Phase II The sample size calculation base Simon optimal two-stage design , minimum success ( 8-week non progression ) rate consider interest p1=60 % uninteresting rate p0=40 % . Assuming type I error alpha 0.05 80 % power , 46 evaluable patient need experimental arm reject null hypothesis H0 : p≤p0 versus alternative hypothesis H1 : p ≥ p1 unilateral situation ( 16 patient Stage I 30 additional patient Stage II ) . With 2:1 randomization base assumption 5 % patient may non-evaluable , total 72 patient include study : 48 patient Arm A - experimental 24 patient Arm B - control ) . DATA ENTRY , DATA MANAGEMENT AND STUDY MONITORING All data concern patient record electronic case report form ( eCRF ) throughout study . serious adverse event ( SAE ) reporting also paper-based e-mail and/or Fax . The sponsor perform study monitor help investigator conduct study compliance clinical trial protocol , Good Clinical Practices ( GCP ) local law requirement .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Postmenopausal female patient time consent Histologicallyconfirmed diagnosis advance recurrent endometrial carcinoma , amenable curative treatment . Carcinosarcoma eligible . Documented estrogen receptor and/or progesterone receptor positive endometrial cancer . Hormone receptor positivity define accord routine practice participate site . Availability pretreatment tumor sample ( archival formalinfixed paraffinembedded ( FFPE ) block fresh biopsy feasible ) presence least one biopsiable tumor lesion ontreatment biopsy Documented disease progression one prior firstline chemotherapy regimen and/or 2 line endocrine therapy metastatic set Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 minimum life expectancy 8 week At least one measurable lesion accord response evaluation criterion solid tumor ( RECIST 1.1 ) Adequate bone marrow , renal liver function show : Absolute neutrophil count &gt; 1.5 x 109/L , Platelets &gt; 100 x 109/L , Hemoglobin ( Hb ) &gt; 9 g/dL Serum bilirubin ≤ 1.5 upper limit normal ( ULN ) , alanine aminotransferase aspartate aminotransferase ≤ 2.5 ULN ( ≤ 5 ULN patient liver metastasis ) Creatinine clearance &gt; 50 mL/min ( use Cockcroft formula , MDRD formula patient 65 year Appendix 3 Creatinine Clearance ) Fasting serum cholesterol ≤ 300 mg/dL ( 7.75 mmol/L ) AND fast triglyceride ≤ 2.5 ULN ( lipidlowering drug allow ) , Fasting plasma glucose ≤7 mmol/L ( 126 mg/dL ) Recovered prior significant treatmentrelated toxicity i.e . persistent treatmentrelated toxicity &gt; Grade 1 per Common Terminology Criteria Adverse Events ( CTCAE ) v4.3 , except grade 2 alopecia , grade 2 anemia Hb &gt; 9 g/dL . Minimal washout period start study drug follow treatment : Any anticancer treatment approve investigational medicinal product : &gt; 21 day Any chemotherapy , radiation therapy , androgen : &gt; 21 day ( include palliative radiotherapy focal site ) . Any monoclonal antibody therapy : &gt; 4 week Major surgery : &gt; 4 week Minor surgery ( exclude tumour biopsy ) &gt; 14 day . Any haemopoietic growth factor ( e.g. , filgrastim [ granulocyte colonystimulating factor ( GCSF ) ] , sargramostim [ granulocytemacrophage colonystimulating factor ( GMCSF ) ] ) : &gt; 14 day Vaccinated live , attenuated vaccine : &gt; 4 week . Sensitive narrow therapeutic range substrate drug metabolise enzyme Cytochrome P4502C8 ( CYP2C8 ) , Cytochrome P4502C9 ( CYP2C9 ) , Cytochrome P4502C19 ( CYP2C19 ) , Cytochrome P4502D6 ( CYP2D6 ) drug transporter Pglycoprotein ( Pgp ) ( multidrug resistance ( MDR1 ) ) , breast cancer resistance protein ( BCRP ) , organic aniontransporting polypeptide 1B1 ( OATP1B1 ) , organic aniontransporting polypeptide 1B3 ( OATP1B3 ) , organic cation transporter 1 ( OCT1 ) organic cation transporter 2 ( OCT2 ) Potent moderate inhibitor inducer CYP3A4/5 , Pgp ( MDR1 ) BCRP Restricted CYP transporter related comedications Patient willing follow sunlightprotection measure . Patients advise need sunlight protection measure administration AZD2014 , advise adopt measure period 3 month receive final dose AZD2014 . Patient able willing provide inform consent ability understand willingness followup visit . Covered medical insurance Patient pretreated nonsteroidal aromatase inhibitor Active uncontrolled symptomatic central nervous system metastases spinal cord compression Clinically relevant abnormal level potassium sodium . Use forbidden concomitant treatment treatment period : Any anticancer treatment ( approved investigational ) mention protocol Chronic treatment corticosteroid immunosuppressive agent . Stable low dose corticosteroid allow ( unless contraindicate ) provide initiate last disease progression start least 4 week prior study treatment . Topical inhale corticosteroid allow . Potent moderate inhibitor inducer CYP3A4/5 , Pgp ( MDR1 ) BCRP ( see Appendix 5 Restricted CYP transporter related comedications ) Sensitive narrow therapeutic range substrate drug metabolise enzyme CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 drug transporter Pgp ( MDR1 ) , BCRP , OATP1B1 , OATP1B3 , OCT1 OCT2 outside wash period restriction present Appendix 5 Restricted CYP transporter related comedications ) Patient know hypersensitivity anastrozole excipients ( Lactose monohydrate , Povidone , Sodium starch glycollate , Magnesium stearate , Hypromellose , Macrogol 300 , Titanium dioxide ) History hypersensitivity active inactive excipients AZD2014 drug similar chemical structure class AZD2014 History malignancy except basal cell squamous cell skin cancer , situ cervical cancer , unless diseasefree least five year Patient severe and/or uncontrolled medical condition : Recent history specific cardiovascular event , laboratory parameter may affect cardiac parameter include : unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior start study drug , serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease ; Symptomatic congestive heart failure New York heart Association Class III IV Mean rest correct QT interval ( QTc ) , calculate use Fridericia 's formula , &gt; 470 msec obtain 3 electrocardiogram ( ECGs ) , family personal history long short QT syndrome , Brugada syndrome know history QTc prolongation Torsade de Pointes within 12 month patient enter study Abnormal cardiac function baseline : leave ventricular ejection fraction ( LVEF ) &lt; 50 % shorten fraction ( SF ) &lt; 15 % . Any evidence interstitial lung disease uncompensated respiratory condition . Active ( acute chronic ) uncontrolled severe infection , liver disease cirrhosis , decompensated liver disease , active chronic hepatitis ( i.e . quantifiable hepatitis B virus ( HBVDNA ) and/or positive HbsAg , quantifiable hepatitis C virus ( HCVRNA ) ) , Active , bleed diathesis Current refractory nausea vomiting , chronic gastrointestinal disease , inability swallow formulate product previous significant bowel resection would preclude adequate absorption AZD2014 . Rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Type 1 uncontrolled Type 2 diabetes Preexisting renal disease include glomerulonephritis , nephritic syndrome , Fanconi Syndrome renal tubular acidosis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Clinical Trials , Randomized</keyword>
	<keyword>Clinical Trial , Phase I</keyword>
	<keyword>Clinical Trial , Phase II</keyword>
	<keyword>Multicenter Trials</keyword>
	<keyword>Aromatase Inhibitors</keyword>
	<keyword>mTOR kinase inhibitor</keyword>
</DOC>